Hematology/Oncology Pharmacy Association (HOPA) | Strategic Alliance Partners

A drug recycling program can help increase patient access and minimize waste of expensive oral cancer medications.

Promising investigational oncology drugs include oral taxanes, small molecule drugs, and immunotherapies.

Common factors that contributed to reported increased dissatisfaction at work include role conflict, quantity of work, workflow disruptions, organizational culture, and leadership support.

Even while therapeutically anticoagulated, patients with cancer have risk factors for recurring venous thromboembolism and bleeding, according to a session at the Hematology/Oncology Pharmacy Association 2021 Virtual Annual Conference.

A session at the Hematology/Oncology Pharmacy Association Virtual Annual Conference provided an overview of how treatment options are changing with potential new therapies in development for patients with non-small cell lung cancer.

Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.

Although many attendees and presenters are looking forward to returning to in-person conferences in the future, Anne Krolikowski said the virtual format of their upcoming conference allows even more people to attend.

As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape.

Understanding the role of abemaciclib (Verzenio) in managing patients with hormone receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer is crucial.

Amid rising cancer care costs, a focus on chemotherapy stewardship may result in cost savings, according to a session of the HOPA Practice Management 2020 Virtual Learning Event.

In outpatient breast cancer clinics, oral chemotherapies are becoming more common for various malignancies, but hematologic and non-hematologic toxicities can cause challenges for patients.

Oral oncolytics has become increasingly common as treatment for patients with cancer over the past several years.

The objective of the study was to develop an education program that increased confidence and knowledge of pharmacists managing CDK4/6 inhibitors.

In the oral chemotherapy setting, pharmacist care exceeded patients’ expectations and helped manage and avoid adverse events (AEs).

Kirollos Hanna, PharmD, BCPS, BCOP, explains antibody drug conjugates and their method of action. This video was filmed at the Hematology/Oncology Pharmacists Association 2020 Meeting in Tampa, Florida.

Pharmacy Times will be on-site next week to provide coverage of the sessions, recaps of the panel discussions, and interviews with the experts.